FLU STRAINS CHANGE FROM YEAR TO YEAR.

OUR TRUSTED PARTNERSHIP REMAINS THE SAME.



Every March, FDA selects strains for the U.S. that go into the flu vaccines.¹

CDC and global surveillance data show B/Yamagata lineage viruses haven't been detected since March 2020.²

FDA and WHO have strongly recommended that the "inclusion of a **B/ Yamagata lineage antigen** in quadrivalent influenza vaccines **is no longer warranted**, and every effort should be made to exclude this component as soon as possible."^{2,3}

Therefore, **FDA announced that only trivalent influenza vaccines will be available** in the U.S. for the 2024-2025 flu season.

We are committed to providing uninterrupted supply and timely delivery to our customers with our 2 separate, secure locations for manufacturing vaccines.

PREBOOK NOW

For more information on GSK's Trivalent Influenza Vaccines, view the product information on gskpro.com. To Prebook, go to gskdirect.com.



Online at GSKDirect.com





Contact your GSK Vaccines Sales Representative

CDC=Centers for Disease Control and Prevention; FDA=Food and Drug Administration; WHO=World Health Organization.

References: 1. Centers for Disease Control and Prevention. Influenza (flu). Selecting viruses for the seasonal influenza vaccine. Reviewed November 3, 2022. Accessed February 2, 2024. https://www.cdc.gov/flu/prevent/vaccine-selection.htm#print

2. Centers for Disease Control and Prevention. Influenza (flu). Information for the 2023-2024 flu season. Reviewed January 16, 2024. Accessed February 2, 2024. https://www.cdc.gov/flu/season/faq-flu-season-2023-2024.htm 3. U.S. Food & Drug Administration. Challenges and opportunities for vaccine strain composition with the reduced public health threat from influenza B/Yamagata lineage viruses. Vaccines and Related Biological Products Advisory Board. October 5, 2023. https://www.fda.gov/media/172762/download

Trademarks are owned by or licensed to the GSK group of companies.

